FDA grants orphan drug designation to potential treatment of STXBP1 developmental and epileptic encephalopathy
Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Zura Bio submits protocol to FDA for Phase 2 study of Tibulizumab
Zura Bio (ZURA) “announced the submission of a protocol to its open Investigational New Drug application with the U.S. Food and Drug ...
ophthalmologyadvisor8h
Photobiomodulation Treatment Receives FDA Authorization for Dry AMD Therapy
The Valeda ® Light Delivery System (LumiThera, Inc.) is the first ever FDA-authorized treatment for vision loss in dry AMD, the manufacturer reported. The technology was evaluated in the LIGHTSITE III ...
FierceBiotech15h
Boston Pharma hits phase 2 MASH goal, positioning monthly prospect to follow Akero, 89bio into pivotal trials
Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...